Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin nasal spray crossover trial in Prader-Willi syndrome
ACTRN12609000982213Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Prader-Willi syndrome (PWS) (2 arms), sponsored by University of Sydney. Primary endpoints: Eating behaviours (hyperphagia and pica), Rages/tantrums and 1 more. Started Mar 2010; status: completed.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on ACTRN12609000982213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000982213.